Comprehensive review of cannabis withdrawal: symptoms, brain mechanisms, gender differences, and treatment options | Research

The takeaway

Cannabis withdrawal is a recognized clinical syndrome with mood and behavioral symptoms of light to moderate intensity, driven by CB1 receptor downregulation that reverses within 4 weeks of abstinence, with women reporting more severe symptoms including physical complaints.

Read this if you want a thorough, evidence-based understanding of what cannabis withdrawal involves and how to manage it.

CB1 receptors begin recovering within 2 days and normalize within 4 weeks of abstinence

What the researchers found

The review synthesized evidence that regular cannabis use causes desensitization and downregulation of brain CB1 receptors, which begins reversing within the first 2 days of abstinence and normalizes within about 4 weeks. This receptor recovery timeline may define the neurobiological duration of the cannabis withdrawal syndrome.

Severity depends on the amount used before cessation, gender, genetic factors, and environmental influences. Women reported stronger withdrawal than men, including physical symptoms like nausea and stomach pain that are less prominent in males.

For treatment, gabapentin and THC analogs showed the most promise. Mirtazapine helped with withdrawal-related insomnia. Notably, venlafaxine worsened withdrawal symptoms, while other antidepressants, atomoxetine, lithium, buspirone, and divalproex had no relevant effect.

Why it matters

Cannabis withdrawal is now recognized in the DSM-5, but many people and clinicians still doubt its existence. This review provides a thorough neurobiological framework showing why withdrawal occurs (receptor downregulation), how long it lasts (the 4-week CB1 recovery window), and what treatments help. The gender differences are particularly important for tailoring clinical approaches.

The numbers in context

CB1 receptor recovery: begins within 2 days, normalizes within ~4 weeks of abstinence. Women report stronger symptoms. Promising treatments: gabapentin, THC analogs. Helpful for insomnia: mirtazapine. Harmful: venlafaxine. Ineffective: other antidepressants, atomoxetine, lithium, buspirone, divalproex.

How the study worked

Comprehensive narrative review synthesizing animal and human evidence on cannabis withdrawal syndrome. Covers neurobiology (CB1 receptor changes), clinical presentation, gender differences, severity determinants, treatment approaches, and diagnostic criteria.

What this study cannot tell us

Narrative review, not systematic, so coverage may be selective. The evidence base for pharmacological treatments is small. The 4-week CB1 recovery timeline may not account for longer-term synaptic changes. Individual variation in withdrawal severity is high, making generalizations difficult.

How to read the evidence

Comprehensive narrative review synthesizing animal and human data from multiple study types. Provides strong overview but individual treatment recommendations rest on small studies.

When this study was published

Published in 2017. Cannabis withdrawal research has continued to develop, particularly regarding the impact of high-potency products.

The bigger picture

The 4-week CB1 receptor recovery timeline provides a concrete neurobiological anchor for understanding why withdrawal typically lasts about a month. It also explains why tapering with THC analogs can be effective: gradually reducing CB1 stimulation allows the receptors to upregulate without the full shock of abrupt cessation.

Questions still open

Would the increasing potency of modern cannabis products change the withdrawal timeline? Could CB1 receptor density be measured to predict withdrawal severity? Are there effective behavioral interventions (exercise, psychoeducation) that complement pharmacological approaches?

Common questions

Is cannabis withdrawal real?

Yes. Cannabis withdrawal is recognized in the DSM-5 and involves mood and behavioral symptoms typically of light to moderate intensity. It is driven by measurable changes in brain cannabinoid receptors that occur with regular use and reverse during abstinence.

Why do women experience worse cannabis withdrawal?

The review found that women reported stronger withdrawal symptoms including physical complaints like nausea and stomach pain. The exact reasons are not fully understood but likely involve sex differences in cannabinoid receptor biology, hormonal interactions, and potentially differences in patterns of use.

Read the original research

The cannabis withdrawal syndrome: current insights.

Substance abuse and rehabilitation, 8, 9-37

View on PubMed ↗Publisher’s paper ↗

Citation

Bonnet, Udo; Preuss, Ulrich W. (2017). The cannabis withdrawal syndrome: current insights.. Substance abuse and rehabilitation, 8, 9-37. https://doi.org/10.2147/SAR.S109576